Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
A weight loss drug developer's stock soars
A weight loss drug developer's stock soars after a $198 million IPO
Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday.
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO
Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share.
BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
Ozempic could lower risk of opioid overdoses, says new study
Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
The results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose.
Ozempic May Decrease Opioid Overdose Risk, Study Suggests: What To Know
Patients taking Ozempic were about 60% less likely to have an opioid overdose compared to those taking other diabetes drugs.
6h
Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...
2d
on MSN
Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next
Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an ...
20h
on MSN
James Corden admits turning to weight loss drug Ozempic in a bid to slim down
The Gavin and Stacey star has come to the realisation that ‘nothing about my eating has anything to do with being hungry’ ...
2d
Ozempic maker to testify before Senate committee on weight loss drug prices
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
Axios
2d
Ozempic maker's CEO blames insurance companies for weight-loss drug prices
The chief executive of the company behind Ozempic and Wegovy blamed insurers and middlemen for the high costs of weight-loss ...
In Depth
1d
In Depth
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...
6h
James Corden shares results after trying Ozempic for weight loss
James Corden revealed that he gave Ozempic a try to help with weight loss, but soon found that his relationship with food had ...
1h
LifeVantage Completes Successful Human Clinical Trial with New GLP-1 System for Activated Weight Loss*
Results of the human clinical trial will be shared with LifeVantage Consultants at Market Connect in Kansas City, October ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Novo Nordisk
Ozempic
Wegovy
United States
Bernie Sanders
Feedback